title: Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: a safe and effective adjunctive therapy.
abstract: OBJECTIVE
  Abciximab has been shown to decrease periprocedural ischemic complications after coronary intervention. However, the adjunctive use of abciximab in carotid stenting has not been adequately studied. We sought to determine the efficacy and safety of abciximab in carotid stenting.
  
  
  METHODS
  Carotid stenting was performed in 151 consecutive patients determined to be at high surgical risk by a vascular surgeon. Of these, 128 consecutive patients received adjuvant therapy with abciximab (0.25 mg/kg bolus before the lesion was crossed with guidewire and 0.125 micro. kg(-1). min(-1) infusion for 12 hours.). A heparin bolus of 50 U/kg was given, and activated clotting time was maintained between 250 to 300 seconds. All patients received aspirin and thienopyridine. Procedural and 30-day outcomes were compared between the control (n=23) and abciximab (n=128) groups.
  
  
  RESULTS
  The 2 groups had similar baseline characteristics. Procedural events were more frequent in the control group (8%; 1 major stroke and 1 neurological death) compared with the abciximab group (1.6%; 1 minor stroke and 1 retinal infarction; P=0.05). On 30-day follow-up, 1 patient presented with delayed intracranial hemorrhage in the abciximab group. There were no other major bleeding complications.
  
  
  CONCLUSIONS
  Adjunctive use of abciximab for carotid stenting is safe with no increase in the risk of intracranial hemorrhage. This adjunctive therapy with potent glycoprotein IIb/IIIa inhibition may help to reduce periprocedural adverse events in patients undergoing carotid stenting.
authors.affiliation: Department of and Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
authors.forename: S R
authors.initials: SR
authors.lastname: Kapadia
authors.forename: C T
authors.initials: CT
authors.lastname: Bajzer
authors.forename: K M
authors.initials: KM
authors.lastname: Ziada
authors.forename: D L
authors.initials: DL
authors.lastname: Bhatt
authors.forename: O M
authors.initials: OM
authors.lastname: Wazni
authors.forename: M J
authors.initials: MJ
authors.lastname: Silver
authors.forename: E G
authors.initials: EG
authors.lastname: Beven
authors.forename: K
authors.initials: K
authors.lastname: Ouriel
authors.forename: J S
authors.initials: JS
authors.lastname: Yadav
mesh_terms: D000077284:Abciximab; D000277:Adjuvants, Pharmaceutic / Q000627:therapeutic use; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects; D002340:Carotid Artery Diseases / Q000601:surgery*; D005260:Female; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use*; D020300:Intracranial Hemorrhages / Q000209:etiology; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D018570:Risk Assessment; D012307:Risk Factors; D015607:Stents / Q000009:adverse effects; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
chemical_list: D000277:Adjuvants, Pharmaceutic; D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014568:Urokinase-Type Plasminogen Activator; D000077284:Abciximab